Acticor Biotech

Acticor Biotech, SAS is making good progress in advancing glenzocimab, a first-in-class treatment which the French group believes will significantly improve outcomes for cardiovascular emergencies, i

Venture capital investors showed biopharmaceutical start-ups and growth-stage private companies some love with a trio of $100m-plus financings announced on 14 and 16 February, including a $236m series

Venture capital investment in biopharmaceutical companies has been on the decline in 2019, but one segment of the industry has seen a big rise in VC funding – cell and gene therapy companies. A recent

Series A Round Brings $60m To 89bio Launched with small molecules licensed from Teva Pharmaceutical Industries Ltd. , 89bio concurrently raised $60m through its Series A round. Founding investors O